Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Welcure Drugs & Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Welcure Drugs & Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹13.4M ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹13.7M ve ₹306.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	n/a
Nakit	₹216.00k
Eşitlik	₹13.40m
Toplam yükümlülükler	₹306.00k
Toplam varlıklar	₹13.71m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 524661 'nin kısa vadeli varlıkları ( ₹318.0K ) kısa vadeli yükümlülüklerini ( ₹306.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: 524661 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 524661 borçsuzdur.

Borcun Azaltılması: 524661 son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: 524661 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 524661 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Welcure Drugs & Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Welcure Drugs & Pharmaceuticals Limited Informs Resignation of Ashish Abbi as Non Executive Independent Director

Less than half of directors are independent

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Welcure Drugs & Pharmaceuticals Limited Approves Shifting of Branch Office of the Company

Welcure Drugs & Pharmaceuticals Limited to Report Q4, 2024 Results on May 28, 2024

New minor risk - Share price stability

Welcure Drugs & Pharmaceuticals Limited Announces the Resignation of Priti Rajesh Kharwar as Additional Director, Effective from March 28, 2024

High number of new and inexperienced directors

Welcure Drugs & Pharmaceuticals Limited Announces Board Resignations

Welcure Drugs & Pharmaceuticals Limited Approves Appointment of Altaf Hussain Shah as Chief Financial Officer

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

High number of new and inexperienced directors

New major risk - Share price stability

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 14, 2023

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Mayank Bhandari as Non Executive and Independent Director

Investor sentiment improves as stock rises 20%

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 28, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q4, 2023 Results on May 29, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 13, 2023

High number of new and inexperienced directors

High number of new directors

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Sudhir Chandra as Managing Director, with Effect from October 8, 2022

Second quarter 2023 earnings released

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2023 Results on Oct 08, 2022

Founder & Non Executive Director recently sold ₹2.3m worth of stock

Welcure Drugs & Pharmaceuticals Limited Announces Chief Financial Officer Changes

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Director

First quarter 2023 earnings released: ₹0.042 loss per share (vs ₹0.02 loss in 1Q 2022)

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2022

Full year 2022 earnings released: EPS: ₹0.02 (vs ₹0.045 in FY 2021)

Less than half of directors are independent

Full year 2022 earnings released: EPS: ₹0.02 (vs ₹0.045 in FY 2021)

First quarter 2022 earnings released

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.05 (vs ₹0.008 loss in FY 2020)

New 90-day low: ₹2.02

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2021 Results on Jan 16, 2021

New 90-day high: ₹2.10

First half earnings released

Welcure Drugs & Pharmaceuticals Limited Announces Appointment of Gagan Juneja as Additional Independent Director

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2021 Results on Oct 16, 2020

New 90-day high - ₹1.94

New 90-day high - ₹0.97

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin